Member Info for arsenal58

Baz
Liberium update was released this AM

The 192 million is Liberiums updated call Baz

Sylvania Platinum Limited (LON:SLP) shareholders, with the covering analyst delivering a significant upgrade to their statutory estimates for the company. The analyst greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals.Following the upgrade, the current consensus from Sylvania Platinum's lone analyst is for revenues of US$192m in 2021 which - if met - would reflect a major 68% increase on its sales over the past 12 months. Statutory earnings per share are presumed to shoot up 147% to US$0.36. Prior to this update, the analyst had been forecasting revenues of US$145m and earnings per share (EPS) of US$0.25 in 2021. There has definitely been an improvement in perception recently, with the analyst substantially increasing both their earnings and revenue estimates.Check out our latest analysis for Sylvania Platinumearnings-and-revenue-growthAIM:SLP Earnings and Revenue Growth January 29th 2021With these upgrades, we're not surprised to see that the analyst has lifted their price target 43% to AU$3.55 per share.Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The analyst is definitely expecting Sylvania Platinum's growth to accelerate, with the forecast 68% growth ranking favourably alongside historical growth of 21% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 3.0% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Sylvania Platinum is expected to grow much faster than its industry.The Bottom LineThe biggest takeaway for us from these new estimates is that the analyst upgraded their earnings per share estimates, with improved earnings power expected for this year. They also upgraded their revenue estimates for this year, and sales are expected to grow faster than the wider market. Given that the consensus looks almost universally bullish, with a substantial increase to forecasts and a higher price target, Sylvania Platinum could be worth investigating further.With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At least one analyst has provided forecasts out to 2023, which can be seen for free on our platform here

Are in here !!!
No shorting for them it is a golden ticket
Directors also shelling out
Big buy

Mango i think you left a paragraph out old chap
This is not curtains for the whole program, and the GSK license for the drug “remains in place,” Immutep said, although the British Big Pharma is now assessing “next steps” for the program. It does have other disease targets outside of UC, including psoriasis.

Lol

Flutter
888
32 Red
Need more BJ
Betway maybe

Flutter 888 32 red
Anymore needed BJ

Great reading your synopsis agree in part with your reasoning
But no American market without the American partner !!!
That is the b all and end of the deal
Lets hope my theory doesn’t come to pass
Would bee a good idea fot ENT to buy a American license and set up a second outfit domiciled inthe US if possible ???

The one problem for Entain is
MGM dropping them for another British Bookie
Yanks never take prisoners
I have sold half my holdings now for a reasonable profit
Will sit tight but not has enamoured with the future as before GLA

21-Jan-21 09:53:24 1,378.00 200,000 Unknown* 1,377.80 1,378.20 3m O Crafty fokkers come to mind

Date Time Trade Prc Volume Buy/Sell Bid Ask Value
21-Jan-21 09:55:35 1,377.80 240 Buy* 1,377.60 1,377.80 3,307 A
21-Jan-21 09:55:35 1,377.80 16 Buy* 1,377.60 1,377.80 220.45 A
21-Jan-21 09:55:16 1,377.60 258 Unknown* 1,377.60 1,377.80 3,554 O
21-Jan-21 09:55:15 1,377.80 100 Sell* 1,377.80 1,378.20 1,378 A
21-Jan-21 09:55:15 1,377.80 390 Sell* 1,377.80 1,378.20 5,373 A
21-Jan-21 09:55:15 1,377.80 130 Sell* 1,377.80 1,378.20 1,791 A
21-Jan-21 09:55:15 1,377.80 81 Sell* 1,377.80 1,378.20 1,116 A
21-Jan-21 09:53:31 1,378.40 15 Buy* 1,378.20 1,378.60 206.76 O
21-Jan-21 09:53:31 1,378.40 5 Buy* 1,378.20 1,378.60 68.92 O
21-Jan-21 09:53:31 1,378.40 7 Buy* 1,378.20 1,378.60 96.49 O
21-Jan-21 09:53:31 1,378.20 33 Sell* 1,378.20 1,378.60 454.81 A
21-Jan-21 09:53:31 1,378.20 40 Sell* 1,378.20 1,378.60 551.28 A
21-Jan-21 09:53:31 1,378.20 278 Buy* 1,378.00 1,378.20 3,831 A
21-Jan-21 09:53:26 1,377.893 101 Sell* 1,377.80 1,378.20 1,392 O
21-Jan-21 09:53:24 1,378.00 200,000 Unknown* 1,377.80 1,378.20 3m O
21-Jan-21 09:53:19 1,378.107 1,000 Buy* 1,377.80 1,378.20 13.78k O
21-Jan-21 09:52:49 1,378.108 100 Buy* 1,377.80 1,378.20 1,378 O
21-Jan-21 09:52:22 1,377.9051 1,000 Sell* 1,377.80 1,378.20 13.78k O
21-Jan-21 09:52:08 1,378.00 413 Sell* 1,378.00 1,378.20 5,691 A
21-Jan-21 09:52:02 1,377.80 4 Sell* 1,378.00 1,378.60 55.11 O
21-Jan-21 09:52:02 1,378.20 250 Sell* 1,378.20 1,378.60 3,446 A
21-Jan-21 09:52:02 1,378.20 129 Sell* 1,378.20 1,378.60 1,778 A
21-Jan-21 09:52:02 1,378.20 21 Sell* 1,378.20 1,378.40 289.42 A
21-Jan-21 09:52:02 1,378.20 117 Buy* 1,377.80 1,378.20 1,612 A
21-Jan-21 09:52:02 1,378.20 100 Buy* 1,377.80 1,378.20 1,378 A
21-Jan-21 09:52:02 1,378.20 211 Buy* 1,377.80 1,378.20 2,908 A
21-Jan-21 09:52:02 1,378.20 174 Buy* 1,377.80 1,378.20 2,398 A
21-Jan-21 09:51:34 1,378.00 111 Unknown* 1,377.80 1,378.20 1,530 O
21-Jan-21 09:51:34 1,377.80 1 Sell* 1,377.80 1,378.20 13.78 O
21-Jan-21 09:51:34 1,378.00 70 Buy* 1,377.80 1,378.00 964.60 A
21-Jan-21 09:51:34 1,378.00 200 Buy* 1,377.80 1,378.00 2,756 A
21-Jan-21 09:51:34 1,378.00 566 Sell* 1,378.00 1,378.20 7,799 A
21-Jan-21 09:51:16 1,378.00 1 Sell* 1,378.00 1,378.40 13.78 O
21-Jan-21 09:51:16 1,378.20 2 Unknown* 1,378.00 1,378.40 27.56 O
21-Jan-21 09:51:16 1,378.00 1 Sell* 1,378.00 1,378.40 13.78 O
21-Jan-21 09:51:16 1,378.20 200 Sell* 1,378.20 1,378.40 2,756 A
21-Jan-21 09:51:16 1,378.20 293 Sell* 1,378.20 1,378.40 4,038 A
21-Jan-21 09:51:16 1,378.20 119 Sell* 1,378.20 1,378.40 1,640 A
21-Jan-21 09:51:16 1,378.20 171 Sell* 1,378.20 1,378.40 2,357 A
21-Jan-21 09:51:16 1,378.20 293 Buy* 1,378.00 1,378.20 4,038 A
21-Jan-21 09:51:09 1,377.846 200 Sell* 1,378.00 1,378.40 2,756 O
21-Jan-21 09:51:10 1,378.20 150 Unknown* 1,378.00 1,378.40 2,067 A
21-Jan-21 09:51:10 1,378.20 191 Unknown* 1,378.00 1,378.40 2,632 A
21-Jan-21 09:51:10 1,378.20 250 Unknown* 1,378.00 1,378.40 3,446 A
21-Jan-21 09:51:10 1,378.20 50 Unknow

1.35
Why was it so cheap after the last set of figures
Amazing
Only 100 thousand plus shares and no debt crazy
1.65without the recovered mines surely GLA

Lol

https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-nhs-supported-agile-study-to-evaluate-vir-7832-in-the-early-treatment-of-covid-19/

Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
For media and investors only

Issued: London UK; San Francisco US

Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment
Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection
Trial targeted to begin in 1Q2021 at multiple sites across the UK
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. VIR-7832 is a neutralising COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection.

The AGILE trial platform, which will be the first to test VIR-7832 in humans, uses adaptable protocols and statistical models to enable the evaluation of candidate medicines for COVID-19 treatment. The initiative is a collaboration between the University of Liverpool, Liverpool School of Tropical Medicine, Liverpool University Hospitals NHS Foundation Trust, University of Southampton and Lancaster University and coordinated by the National Institute for Health Research Southampton Clinical Trials Unit across the UK Clinical Research Facility Network. The trial is due to begin in the first quarter of 2021.

George Scangos, Ph.D., Chief Executive Officer of Vir, said: “We are pleased to have the support of the NHS behind our efforts to evaluate and advance VIR-7832 for the treatment and potential prevention of COVID-19. This study will be critical to our efforts as we work to understand whether the modifications we have made to this monoclonal antibody increase its potency and stimulate a T cell response to not only provide therapeutic benefits but also potentially confer a vaccine-like effect that could be applicable to prophylaxis.”

Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “While vaccine development has been very successful, current infection and hospitalisation rates show that multiple vaccines and therapeutic options will be needed to combat and ultimately end this pandemic. We are grateful to everyone involved in the AGILE study for supporting this important research and expect initial results from the study to provide important insights into the use of VIR-7832 early in the course of infection with SARS-CoV-2.”

VIR-7832 is set to become the second monoclonal antibody from the Vir-GSK collaboration to be investigated as a potential COVID-19 treatment. The first antibody, VIR-7831, is currently being investigated in two g

Pulled the bid totally ooohps

Didn’t expect that wow
My average was 68
I have dumped my 10k
How the market can deceive !!!

Thanglan
The withdrawal function is working this AM

Not sure they will
More likely share buybacks
Bigger divis for a few years

Interims 19th January if they are not taken out by then !!
Price to Net asset value is amazing !!
A absolute snip at a pound a share